Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · melanoma-umap@29

SRR10900576

—

7551f729-0b59-5df4-ba55-d4c441f00884

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.600
  • ALLOGRAFT_REJECTION+0.500
  • ANGIOGENESIS+0.500
  • COAGULATION+0.500
  • COMPLEMENT+0.500
  • INFLAMMATORY_RESPONSE+0.500
  • INTERFERON_GAMMA_RESPONSE+0.500
  • TNFA_SIGNALING_VIA_NFKB+0.500
  • ANDROGEN_RESPONSE+0.400
  • APOPTOSIS+0.400

Top 10 suppressed

  • DNA_REPAIR-0.300
  • MYC_TARGETS_V2-0.300
  • OXIDATIVE_PHOSPHORYLATION-0.300
  • UNFOLDED_PROTEIN_RESPONSE-0.200
  • BILE_ACID_METABOLISM-0.100
  • E2F_TARGETS-0.100
  • MYC_TARGETS_V1-0.100
  • WNT_BETA_CATENIN_SIGNALING-0.100
  • FATTY_ACID_METABOLISM+0.000
  • G2M_CHECKPOINT+0.000

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant

#SampleCancer typeSubtypecos similarity
1BS_593HEWBF
brain-umap@2
Ganglioglioma—0.946
2MNG918
mng-umap@100
——0.932
3EPT0509
medullo-epn-umap@date-based
EPNEPN Tumor0.931
4s0122206
melanoma-umap@29
——0.927
5MNG639
mng-umap@100
——0.925
6C3L-02601
lung-landscapes@6
—cohortA10.921
7BS_TK84K675
brain-umap@2
high-grade glioma—0.920
8BS_YY5B2XDD
brain-umap@2
pilocytic astrocytoma—0.919
9SRR10900559
melanoma-umap@29
——0.910
10MDT-AP-2651
medullo-epn-umap@date-based
MedMedulloblastoma0.908

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 38 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.600Inavolisib— uncovered
ALLOGRAFT_REJECTION0.500Idelalisib— uncovered
ANGIOGENESIS0.500Remibrutinib— uncovered
COAGULATION0.500Binimetinib— uncovered
COMPLEMENT0.500Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.500Idelalisib— uncovered
INTERFERON_GAMMA_RESPONSE0.500Idelalisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.500Inavolisib— uncovered
ANDROGEN_RESPONSE0.400Inavolisib— uncovered
APOPTOSIS0.400Idelalisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.400Remibrutinib— uncovered
HYPOXIA0.400Idelalisib— uncovered
IL2_STAT5_SIGNALING0.400Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.400Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.400Inavolisib— uncovered
KRAS_SIGNALING_UP0.400Inavolisib— uncovered
TGF_BETA_SIGNALING0.400Inavolisib— uncovered
APICAL_JUNCTION0.300Inavolisib— uncovered
APICAL_SURFACE0.300Temsirolimus— uncovered
ESTROGEN_RESPONSE_EARLY0.300Inavolisib— uncovered